Heart failure & cardiomyopathies
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial
Authors' conclusion
Treatment with mavacamten for 48 weeks in nHCM patients was associated with marked biomarker improvements compared with placebo.
Study context
- Population
- Symptomatic adults with nonobstructive hypertrophic cardiomyopathy (nHCM)randomized
- Participants
- 580 adults
- Comparison
- Mavacamten vs placebo
Methodological detailsexploratory analysis
- Exploratory analysis
Primary result
As reported in the abstract
Change in NT-proBNP and hs-cTnI · week 48
Mavacamten vs PlaceboGeometric mean ratio (95% CI)P value
NT-proBNP; 58% reduction
0.42(0.37–0.47)
P < 0.001hs-cTnI; 51% reduction
0.49(0.45–0.53)
P < 0.001Further findings
Baseline biomarkers
ng/L
- NT-proBNP, median (IQR 463-1,725 ng/L)
- 917.5
- hs-cTnI, median (IQR 14.4-91.7 ng/L)
- 29.1
- Female sex, BMI, NYHA class, maximal LV wall thickness, left atrial volume index and E/e' associated with higher baseline NT-proBNP (multivariable)
- Only younger age and LV mass index associated with higher baseline hs-cTnI
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial. J Am Coll Cardiol. Published 27 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it